Selective acetyl-coa carboxylase 1 inhibitor improves hepatic steatosis and hepatic fibrosis in a preclinical nonalcoholic steatohepatitis model

HIGHLIGHTS

• who: / and colleagues from the (UNIVERSITY) have published the paper: Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model, in the Journal: (JOURNAL)
• what: The authors investigated the effects of a ACC1 for treating NAFLD/NASH using preclinical in vitro and in vivo models. reduced MCoA content and inhibited the incorporation of_[14C] acetate into fatty acids in HepG2 cells. This model shows multiple histopathological features common to patients with NASH, including hepatic steatosis, inflammation, and fibrosis.
• how: The authors investigated the effects of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.